Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Habib Hamidi

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Gynecologic Oncology|March 27, 2016
Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signaturesBoris Winterhoff, Habib Hamidi, Chen Wang, et al.
Cancer Immunology Research|May 8, 2025
Identification of the distinct immune microenvironment features associated with progression following high dose melphalan and autologous stem cell transplant in multiple myelomaParvathi Sudha, Travis S Johnson, Habib Hamidi, et al.
Nature Communications|May 9, 2025
Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancerXueping Qu, Habib Hamidi, Radia M Johnson, et al.
Anticancer Research|July 31, 2013
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivityJoshua E Logan, Nikayeh Mostofizadeh, Amrita J Desai, et al.
Journal of the National Cancer Institute|October 2, 2014
Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancerGottfried E Konecny, Chen Wang, Habib Hamidi, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 5, 2021
Quantification of Glomerular Structural Lesions: Associations With Clinical Outcomes and Transcriptomic Profiles in Nephrotic SyndromeJeffrey B Hodgin, Laura H Mariani, Jarcy Zee, et al.
Haematologica|May 11, 2023
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trialSrdan Verstovsek, Lynda Foltz, Vikas Gupta, et al.
European Urology|April 26, 2026
Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell CarcinomaWenxin Xu, Brian I Rini, Laurence Albiges, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 16, 2026
Obesity Accelerates Multiple Myeloma Progression in Certain Mouse Models and in HumansHeather Fairfield, Catherine R Marinac, Habib Hamidi, et al.
Blood Neoplasia|May 11, 2026
Microenvironmentally derived fatty acid-binding proteins 4 and 5 are novel therapeutic vulnerabilities in multiple myelomaHaylee Duval, Katherine Knox, Heather Fairfield, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Gynecologic Oncology|March 27, 2016
Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signaturesBoris Winterhoff, Habib Hamidi, Chen Wang, et al.
Cancer Immunology Research|May 8, 2025
Identification of the distinct immune microenvironment features associated with progression following high dose melphalan and autologous stem cell transplant in multiple myelomaParvathi Sudha, Travis S Johnson, Habib Hamidi, et al.
Nature Communications|May 9, 2025
Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancerXueping Qu, Habib Hamidi, Radia M Johnson, et al.
Anticancer Research|July 31, 2013
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivityJoshua E Logan, Nikayeh Mostofizadeh, Amrita J Desai, et al.
Journal of the National Cancer Institute|October 2, 2014
Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancerGottfried E Konecny, Chen Wang, Habib Hamidi, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 5, 2021
Quantification of Glomerular Structural Lesions: Associations With Clinical Outcomes and Transcriptomic Profiles in Nephrotic SyndromeJeffrey B Hodgin, Laura H Mariani, Jarcy Zee, et al.
Haematologica|May 11, 2023
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trialSrdan Verstovsek, Lynda Foltz, Vikas Gupta, et al.
European Urology|April 26, 2026
Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell CarcinomaWenxin Xu, Brian I Rini, Laurence Albiges, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 16, 2026
Obesity Accelerates Multiple Myeloma Progression in Certain Mouse Models and in HumansHeather Fairfield, Catherine R Marinac, Habib Hamidi, et al.
Blood Neoplasia|May 11, 2026
Microenvironmentally derived fatty acid-binding proteins 4 and 5 are novel therapeutic vulnerabilities in multiple myelomaHaylee Duval, Katherine Knox, Heather Fairfield, et al.
Pageof 5